These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37298704)

  • 1. Potentiating the Cross-Reactive IFN-γ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine.
    Seo YB; Ko A; Shin D; Kim J; Suh YS; Na J; Ryu JI; Lee S; Oh MJ; Sung YC
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing humoral immunity and CD4
    Shen CF; Fu YC; Ho TS; Chen PL; Lee NY; Tsai BY; Tsai PJ; Ko WC; Liu CC; Cheng CM; Shieh CC
    Clin Immunol; 2023 Jun; 251():109342. PubMed ID: 37100338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults.
    Ahn JY; Lee J; Suh YS; Song YG; Choi YJ; Lee KH; Seo SH; Song M; Oh JW; Kim M; Seo HY; Kwak JE; Youn JW; Woo JW; Shin EC; Sung YC; Park SH; Choi JY
    Lancet Microbe; 2022 Mar; 3(3):e173-e183. PubMed ID: 35156068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
    Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q
    Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
    Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant.
    Heinen N; Marheinecke CS; Bessen C; Blazquez-Navarro A; Roch T; Stervbo U; Anft M; Plaza-Sirvent C; Busse S; Klöhn M; Schrader J; Vidal Blanco E; Urlaub D; Watzl C; Hoffmann M; Pöhlmann S; Tenbusch M; Steinmann E; Todt D; Hagenbeck C; Zimmer G; Schmidt WE; Quast DR; Babel N; Schmitz I; Pfänder S
    Front Immunol; 2022; 13():1062210. PubMed ID: 36618413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.
    Sharifi Aliabadi L; Karami M; Barkhordar M; Hashemi Nazari SS; Kavousi A; Ahmadvand M; Vaezi M
    Front Immunol; 2023; 14():1237916. PubMed ID: 37593732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
    Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
    Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
    Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
    Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia.
    Fu JYL; Pukhari MH; Bador MK; Sam IC; Chan YF
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.
    Rice A; Verma M; Voigt E; Battisti P; Beaver S; Reed S; Dinkins K; Mody S; Zakin L; Tanaka S; Morimoto B; Olson CA; Gabitzsch E; Safrit JT; Spilman P; Casper C; Soon-Shiong P
    Front Immunol; 2022; 13():910136. PubMed ID: 35911728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.
    Rouers A; Wong N; Goh YS; Torres-Ruesta A; Tay MZ; Chang ZW; Fong SW; Neo V; Kam IKJ; Yeo NK; Huang Y; Loh CY; Hor PX; Wong JXE; Tan YJ; ; Macary PA; Qian X; Bei W; Ngoh EZX; Salleh SNM; Wang CI; Poh XY; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Lim C; Teo J; Ren EC; Lye DC; Young BE; Ng LFP; Renia L
    J Med Virol; 2023 Jan; 95(1):e28258. PubMed ID: 36305052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea.
    Widyasari K; Jang J; Lee S; Kang T; Kim S
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 1):1013-1024. PubMed ID: 36261313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.